Thousands of red drugs were established on 30 april 2003 and were listed on 18 february 2011 at the shenzhen stock exchange, both registered and located in changzhou city, jiangsu province. The company is an important producer of heparin raw materials and preparations in the country and has technical and scale advantages in the field of heparin products。
The main operation of the thousands of red medicine is the development, production and sale of dry-dry powder, cold-dry powder (including anti-oncological drugs), small-volume injections (non-final sterilization), tablets, hard capsules, granules, raw-material drugs within the licence for the production of medicines. The industry of shinwan is a pharmaceutical-chemical-chemical agent, which covers the concepts of hepatin, cancer resistance, tumour therapy, etc。
Business performance: revenue industry 46, net profit industry 28
In 2025, the revenue from the operation of thousands of red pharmaceuticals was 1,571 million yuan, ranked 46th among 111 companies in the industry, well below $43,612 million for the first chinese medicine and $41,662 million for the second re-sung medicine, and below the industry average of $4,074 million, but above the industry median of $1,170 million. The net profit was $373 million, the industry ranked 28th, the industry ranked 7,717 million, and the industry ranked 2,248 million, which was higher than the industry average of 331 million and the median of 8,2883,000。
The asset-liability ratio was lower than the industry average and the maori ratio was higher than the industry average
In terms of solvency, in 2025, the liability rate for thousands of pharmaceutical assets was 10. 39 per cent, down from 11. 09 per cent in the same period last year, well below the industry average of 35. 54 per cent, indicating a good solvency of companies. In terms of profitability, the corporate māori ratio in 2025 was 58. 36 per cent, up from 54. 85 per cent in the same period last year, and higher than the industry average of 57. 18 per cent, with higher profitability。
There's no data on wang yiu fang's remuneration
The company's controlling shareholders and de facto control are wang yiu's. Mr. Wang yoo fong, a chinese citizen without permanent residence abroad, born in 1953, with university degrees, senior engineers, national chemists and senior economists, began to receive a special allowance from the state council in 1992. For the past five years, he has been chairman of the permanent province's thousands of red biological and chemical pharmaceuticals ltd., and is currently chairman of the chairman and secretary-general of the party and holdings and holdings company's thousands of red biological and chemical pharmaceuticals (hupei) ltd., jiangsu's red biological engineering research institute ltd., changzhou's innocent biomedicine technology ltd., and chairman of changzhou's thousands red investment limited. The general manager, wang qi, received a remuneration of 128. 28 million in 2025, a decrease of 0. 45 million compared to 12. 873 million in 2024。
Number of a shareholders decreased by 1. 17 per cent from the previous period
As at 31 december 2025, the number of shares in the thousands of red medicine a was 7. 28 million, a decrease of 1. 17 per cent compared to the previous period; the number of units in circulation a held by households was 12. 9 million, an increase of 1. 18 per cent over the previous period. As at 31 march 2026, hong kong central clearing company (hkcll) was the third largest mobile shareholder out of the top ten mobile shareholders in the thousands of red pharmaceuticals, holding 3,372,337 shares, a decrease of 1. 92 million compared to the previous period. The south central certificate 1000 etf (512100) withdrew from the top ten circulation shareholders。
East wu securities stated that the company had earned 1,215 million yuan (+0. 61 per cent) in the first three quarters of 2025, with a net profit of 383 million yuan (+23. 79 per cent) to the mother and a net profit of 217 million yuan (+18. 76 per cent) to the non-mother. Single q3 achieves income of $353 million (+0. 35 per cent), net profit of $125 million (-128 per cent) to the mother, and net profit of $7. 2 million (+48. 35 per cent) to the non-mother. Business highlights are as follows: 1. Heparin api price grinds down, formulation operations lead to an overall increase in māori ratio, 61. 13 per cent for single q3 and 2. 71 per cent for ring. 2. The innovation transition has progressed steadily, with the new pharmacological line entering the harvest period, the qhrd 107 capsule entering clinical phase iib in the projected year and the qhrd 106 injection fluid entering clinical phase iii in the expected year. 3. The introduction of a staff equity plan with positive performance and research and development objectives will help to boost staff motivation and accelerate the innovation transformation process. East wu securities adjustment company earned between 2025 and 2027 million yuan to 17. 3/22. 275 million yuan and net profit to the mother to 4. 25/4/220/521 million yuan; the “buy-in” rating is maintained for the current market value p/e valuation 28/28/23x. Risk indicators are lower-than-anticipated downstream demand for raw materials and less-than-anticipated progress in the development of new drugs。
